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STUDY ON THE PREVALENCE OF THYROID 
DYSFUNCTION IN TYPE 1  
DIABETIC CHILDREN 
INTRODUCTION 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease 
resulting in insulin deficiency. In the recent two decades, the world 
wide prevalence of diabetes mellitus (DM) has increased 
significantly.(1) There is a genetic predisposition towards T1DM. This 
also predisposes  these individuals  to other autoimmune diseases such 
as thyroid disease, celiac disease and adrenal insufficiency. Of all the 
above mentioned diseases autoimmune thyroiditis (AIT) is the most 
frequently encountered one.(2, 3) According to various studies, 15-30% 
of T1DM patients have AIT,(4-7) 4-9% have celiac disease and 0.5% 
have Addison disease.(7) 
 
AIT is the most frequent  autoimmune disease seen in diabetic 
children. To diagnose AIT, thyroid peroxidase (anti-TPO) and 
thyroglobulin (anti-TG) antibodies are measured. The prevalence of 
these antibodies depends mainly on sex, age at onset of 
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hypothyroidism and duration of diabetes . Geographic location is an 
important determining factor and the prevalence is high in areas with 
higher iodine intake (De Block et al. 2001). 
AIT  is often clinically silent but it may progress to overt or 
subclinical hypothyroidism or hyperthyroidism(8).. When compared to 
the general population  the positivity of anti-thyroid antibodies  was 
found to range from 2.9% - 3.4%(9,10) while in T1DM children it was 
between 18.5% - 24.6%.(11-13)  These thyroid antibodies may be seen 
just temporarily also.(Vondra et al1996).  
 
According to previous studies age and sex are important risk 
factors to develop AIT, (11,13,14,15,16) while there are very limited studies 
to correlate the age at thyroid diagnosis (11,14), duration of diabetes 
(14,16,17)
 and the development of thyroid antibody positivity. 
EFFECT OF DIABETES ON THYROID FUNCTION 
In T1DM children with normal thyroid function, the T3 and 
TSH levels  may be strongly influenced by the glucose levels . T1DM 
which is poorly controlled may induce a low T3 state and it is  the 
long term diabetic control that determines the T3  and TSH levels.(58) 
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EFFECT OF HYPOTHYROIDISM ON DIABETES 
In children with hypothyroidism the insulin synthesis is 
decreased. Gluconeogenesis is also reduced.It  has been proposed that 
there is a postreceptor defect which explains the decrease in insulin 
stimulated utilization of glucose that occurs in peripheral tissues.This 
predisposes to hypoglycemia in these children.(59)  
Clinical status Effect on blood 
glucose 
Effect onThyroid 
function  
T1DM- 
With normal thyroid 
function 
 ↓ T3  
↓ TSH  
 
TIDM–  in  
hyperthyroidism 
individuals 
 
Poor control of 
glucose 
↑ risk of ocular 
involvement 
Hyperthyroidism – In 
euglycemic children  
Glucose intolerance  
 
Overt diabetes  
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Hypothyroidism- in 
diabetic children 
 Predisposes to 
recurrent 
hypoglycemia 
 
In Type 1 diabetic 
children       
 ↑ Risk of thyroid 
disease 
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Both thyroid hormones and insulin are closely related that 
T1DM and thyroid dysfunction  mutually influence the disease 
process of each other. In hyperthyroidism, it will be difficult to 
maintain the glycemic status thereby making the management of 
diabetes difficult. T1DM children with hyperthyroidism might need a 
increase in daily insulin requirement and hence there is increased risk 
of diabetic ketoacidosis.(18,19) 
  Hypothyroidism usually predisposes to hypoglycemia . 
Hypothyroidism as such causes growth retardation , increase in 
weight,  menstrual irregularities, abnormal lipid elevations and it can 
also lead to cardiac complications in these T1DM children.(8) 
 In previous studies overt hypothyroidism occurs in 1-5% and 
hyperthyroidism occurs in 0.5-7%  individuals.( 3,20)Since  the 
prevalence of AIT is increasing in T1DM children, these children 
should undergo screening either by using TSH or measurement of 
thyroid antibodies. Despite this fact, there is still no clear consensus 
regarding screening of AIT and thyroid function in T1DM.(21) 
In AIT antibodies are produced against thyroglobulin (Tg), a colloid, 
and thyroid peroxidase (anti-TPO), which helps in the formation of 
thyroid hormones (23) 
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In T1DM children, the prevalence  of anti TPO antibody was 
found between 10.3% and 28.4% whereas anti-Tg was found to range 
between 8.8% and 14.5%. (24,25,26,27) In the presence of both of these 
antibodies it was between 5.9%–7%. (24,26,27) These antibodies are 
usually not detected at diagnosis, but they may be seen after sometime 
in the course of the disease particularly in those children who are 
genetically predisposed. (11,17)  In another study, 16.7% of the patients 
was found to have AIT at the onset of diabetes.(17) 
In these children with AIT, family history of diabetes and 
family history of thyroid abnormalities should be taken into account. 
This is because AIT occurs more frequently in individuals with strong 
family history because of genetic predisposition in causing this 
autoimmunity. 
In girls particularly in adolescents, history of menstrual 
irregularities should be asked for, since both delayed and precocious 
puberty is well known to occur. Also features of any specific 
syndrome (Eg: Down syndrome) should be looked for, since AIT is 
more common along with T1DM in these children. 
7 
 
Intake of specific drugs triggering AIT and T1DM should be noted. 
Any stressful event in the form of trauma, infection, exanthematous 
illness also to be looked for. 
 
Nearly one third of all T1DM children  have  co-existent AIT 
and a high prevalence of thyroid dysfunction which is predominantly 
hypothyroidism (clinical or subclinical) whilst a very few have 
hyperthyroidism. Since the prevalence of thyroid dysfunction in 
T1DM children is high, the importance of screening for AIT have 
been emphasized.  
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DEFINITIONS : 
 
Overt hypothyroidism: was defined as elevated TSH and low  T4,  
Subclinical hypothyroidism as elevated TSH and normal T4, 
 
AutoImmuneThyroiditis (AIT) 
Positivity of at least one antibody either TPO or Tg, or 
pathological evidence was considered to be  having AIT.  
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REVIEW OF LITERATURE: 
 
Ardestani et al 
Objective: Studies in different populations have shown great 
variation in the prevalence of thyroid diseases in individuals with 
T1DM. The objective was to study the prevalence of thyroid disorders 
such as autoimmunity of thyroid (AIT), thyroid dysfunction, and 
goiter in children with T1DM 
Findings: The prevalence of subclinical hypothyroidism was 
high in both groups (18%). T1DM patients had lower frequency of 
goiter (21% vs. 38%), and higher prevalence of positive AIT (22% vs 
8%), anti-TPO Ab positivity (19.2% vs. 5.2%), anti-Tg Ab (11.1% vs. 
6.4%) 
Conclusion:  Results demonstrated the high prevalence of AIT 
and thyroid dysfunction in patients with T1DM and regular thyroid 
function and antibody testing was suggested. 
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Kostas kakleas et al 
Anti-TPO  was seen in 17.3% while anti-Tg was 11.1%, and of 
both anti-thyroid antibodies (10.4%). The presence of  anti-thyroid 
antibodies had a positive association with age, duration of diabetes, 
and TSH levels. In general there is a female preponderance for AIT. 
Though the prevalence of AIT was more common in middle aged 
women, it still may start in early childhood. Hence early recognition 
forms an important aspect in the long term management of these 
children. 
Ismael et al Diabetic care: 
Study period: 2001 
Study design: Descriptive study 
.Sample size: 17,749 patients  
Conclusion:  15% patients had AIT. Increase positivity were seen 
during the second decade. 
More common in women. Treatment may be initiated if the 
antibody levels are too high, so that complications of hypothyroidism 
can be prevented. 
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Kordonouri et al, BMJ 
Study period: 1990 - 2003 
Study design: Longitudinal study 
Study population: Children with Type 1 diabetes. 
Methodology:  Antithyroid  antibodies were done in TIDM children 
and   correlated with age, gender and duration of diabetes  
Results: 
When screened initially, 15.4% of patients were positive for 
anti-TPO and 14.4% were positive for  anti-Tg. The  incidence of AIT  
after a decade was significantly higher particularly after 12 years of 
age.  
Individuals with AIT had poor glycemic control and frequent 
admissions. Also the lipid parameters were significantly elevated. 
Already individuals with T1DM are more prone for metabolic 
syndrome complications, and AIT still more worsens it. 
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Guillermo et al, Diabetic care 
Study period:1983-2001 
Study design: Randomized control trial 
Sample size: 58 individuals 
Results: 18 patients developed AIT, and 1 of them developed 
hyperthyroidism. AIT was seen more in females (41%). No significant 
association was found in BMI, lipid parameters, and glycemic control 
in individuals with AIT. 
Those individuals  with  AIT who were promptly managed had 
less complications in terms of cardiovascular, metabolic, menstrual 
irregularities when compared to those individuals who didn’t take 
treatment. 
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Pasupathi et al 
The main objective was to investigate the effect of diabetes on 
thyroid hormone levels and other biochemical variables. The study 
population had 200 subjects  who were divided into two groups: 
diabetic and non-diabetic. A significant increase in the levels of blood 
glucose, HbA1C,  cholesterol, triglyceride were observed in diabetic 
patients compared to non-diabetic subjects. TSH  levels was 
significantly decreased whereas T4 and T3 levels were significantly 
increased in diabetic patients when compared to controls. 
However, the T4 and T3 levels did not differ significantly 
between the two groups. Of the 100 diabetic patients, 27% had low 
thyroid hormone levels, 16% had high thyroid hormones, and 55% had 
normal  levels. This study demonstrated  high incidence of abnormal 
thyroid hormone levels among the diabetics. To conclude ,the 
detection of abnormal thyroid hormone levels in the early stage of 
diabetes mellitus will help the patients to detect the complications 
associated with it. 
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Pranzy et al 
 
The aim of this study was to detect subclinical AIT. The 
presence of antibodies was correlated with the control of diabetes. 
Fifty-one type 1 diabetic patients (mean age 37±11 years, mean 
duration of diabetes 16±13 years) were included into this study. TPO , 
Tg and TSH were measured by RadioImmunoAssay. 
  11 new cases of thyroid dysfunction (22 % of patients) were 
detected by the estimation of thyroid antibodies and TSH. Two new 
cases of hyperthyroidism were diagnosed during the study. In both 
patients with hyperthyroidism the control of diabetes initially 
worsened and improved  after treatment. The screening of antibodies 
in type 1 diabetic patients revealed subclinical cases of AIT . 
Subclinical forms of these disorders have no influence on the control 
of diabetes . It was suggested to follow-up the patients with positive 
antibodies because further deterioration of the thyroid function can be 
expected. 
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STUDY JUSTIFICATION: 
Finding of  hypothyroidism  in our TIDM children attending 
diabetic clinic  when they are routinely screened for the same and 
unavailability of clear data regarding the prevalence of autoimmune 
thyroiditis in these T1DM children prompted us to do the study. We 
have a separate diabetic clinic where the patients are being followed 
up. In their routine screening we found a significant number of cases 
to overt hypothyroidism. In order to have a data for our own diabetic 
children  and to demonstrate the autoimmunity we have decided to do 
this study. 
Although it is generally agreed that because of increasing 
prevalence of  AIT in T1DM children, screening for AIT in all T1DM 
is justified,(4,5) it is still not agreed which is the best method and how 
often to perform. The  American Diabetes Association (6) (7,8) have 
recommended to use TSH as a screening tool in T1DM children once 
a year., as autoantibodies may still persist for many years without 
thyroid dysfunction. 
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  However, the American Diabetes Association have suggested 
that the presence of thyroid autoantibodies increases the risk for 
thyroid disease. These evidences clearly show that the incidence of 
autoimmune thyroid disease is highly increased in T1DM children 
when compared to the general population(7,8) But controversy still 
remains regarding the management when antibodies alone are 
positive. 
From previous studies it is clear that the prevalence of thyroid 
antibodies in patients with type 1 diabetes increases with age, female 
sex and duration of diabetes.(18,19) 
Hence  we confirm the recommendation that thyroid testing be 
done at diagnosis and annually in children with type I diabetes.(30,31)  
Also there are a very few studies which have analysed the risk factors 
to relate AIT with T1DM(3,30) . It is noteworthy that there are limited 
studies to demonstrate the influence of AIT on BMI of children  with 
T1DM. Hence we decided to study the effect of  AIT on the BMI of 
children with T1DM and glycemic control in patients with thyroid 
dysfunction. Also the effect of thyroid dysfunction in these individuals 
was also correlated. 
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AIM OF THE STUDY: 
 To study the prevalence of thyroid dysfunction among children 
with newly diagnosed  Type 1 diabetic children attending 
Diabetic clinic at Institute of Child Health from August 2011 to 
october 2012. 
 To correlate the effect of thyroid dysfunction on age, gender, 
duration of diabetes, glycemic control, lipid abnormality and 
BMI in these T1DM children. 
 
 
 
 
 
 
 
 
 
18 
 
SUBJECTS AND METHODS:  
1.Methodology  
  a) Study design:  
        Descriptive study design  
  b) Place:  
        Diabetic clinic, 
        Institute of Child Health ,Egmore, chennai  
  C) Period of study: 
        August 2011 – October 2012 
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  D) Study population 
Case definition:  
    Diabetes:  Children with   history of polydipsia,  polyphagia,  
polyuria  and  
   Fasting blood glucose ≥126 mg/dl 
   Random blood glucose  ≥200 mg/dl 
Inclusion criteria: All children  attending diabetic clinic at ICH 
who were diagnosed with T1DM. 
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Exclusion criteria: 
I. Children  diagnosed to have secondary diabetes, secondary to 
drugs.( Drugs include steroids, asparaginase, phenytoin )  
II. Children  with dysmorphic or syndromic facies.  
III. Patients found to be having hypothyroidism prior to  diagnosis of 
diabetes 
IV. Neonatal diabetes and in infants less than 1 year. 
 
Sample size: 142 patients  (All consecutive subjects were included) 
Institutional Ethical Committee approval was obtained. 
Informed consent was obtained from each parent  before recruitment 
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  2.Manouvres : 
• Clinical examination of thyroid gland and  Goiter grading was 
done according to WHO/UNICEF/ ICCIDD classification (32) 
 Thyroid profile which includes serum T3, T4,TSH levels 
Serum  T3 and T4 concentrations were measured using Competitive 
chemiluminescent immunoassay.  
Normal range for T3 level: 60 - 200 ng/dl  
T4 : 4.5 – 12 microgram/dl.  
Serum TSH concentrations were determined with ultrasensitive 
sandwich chemiluminescent assay.  
Normal range for TSH level : 0.3-5.5  microU/ml.  
Overt hypothyroidism was defined as elevated TSH and low 
T4, subclinical hypothyroidism as elevated TSH and normal T4, overt 
hyperthyroidism as low TSH and elevated T4 and subclinical 
hyperthyroidism as low TSH and normal T4. 
Serum anti-TPO antibody and anti-Tg antibody were measured 
by solid phase enzyme assay.  
Anti-Tg antibody > 325 IU/ml 
         Anti-TPO concentrations >50 IU/ml, respectively, were 
considered positive.  
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Positivity of at least one antibody was considered  as having AIT.  
Thyroid ultrasonography was done in children with positive  
anti-thyroid antibodies, with or without  elevated TSH . AIT was 
diagnosed when there is  thyroid enlargement (33) with diffuse 
hypoechogenicity and/or diffuse micronodules (34) 
  AIT was diagnosed  when TSH is elevated (>5 µIU/mL), 
associated with the presence of at least one thyroid autoantibody, with 
or without ultrasonographic evidence of thyroiditis.(34) 
 Clinical hypothyroidism is said to be present when there is low T4 
and TSH levels  with or without goitre. 
 Lipid profile :  S. Cholesterol & S.Triglycerides were done. 
S.cholesterol  > 200, S.Triglycerides > 150 was taken as 
abnormal.(20) 
 USG of thyroid gland: Diffuse hypogenecity was suggestive of 
AIT. 
 HbA1C > 10 was taken as having poor control. (27) 
 Hypoglycemic episodes : It was taken as significant when it is 
symptomatic. ( sweating, palpitations and seizures)  
 BMI > 22  was taken as overweight and  >25 as obese. (27) 
  
DIABETIC CHILD WITH GOITRE
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ULTRA SONOGRATHY OF THYROID SHOWING 
HYPOECHOGENECITY 
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3. Statistical analysis 
 Descriptive data was be used to calculate the prevalence. 
 Correlation of thyroid dysfunction on the age, gender, duration 
of diabetes, glycemic  control, effect on BMI and lipid 
abnormality will be calculated using  
A) Univariate analysis 
B) Multivariate analysis  
Quantitative variables are presented as mean±SD .  
Qualitative variables were compared by Chi-square test. Correlation 
between quantitative variables was calculated by  P-value  and <0.05 
was considered statistically significant. 
Data analysis was done using SPSS 16.0 version. 
 
 
 
 
 
 
 OBSERVATIONS
One hundred and forty two children with T1DM
the study.  
 23 (16%) of the diabe
 12 (8%) children
 
 
 
 
 
Subclinical  Cases within overt 
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 Subclinical hyperthyroidism and overt hyperthyroid disease 
was not detected in any case with T1DM .  
 Among the diabetic children 30 (21%) were found positive for 
Anti-TPO antibodies and 21(14%) were positive for Anti Tg 
antibodies.  19 (13%) children were found positive for both 
anti-TPO and anti-Tg antibodies. 
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 The overall prevalence of AIT based on the positivity of any 
one of these antibodies in diabetic children was 32 (22.5%) . 
  Diabetic children with AIT had higher prevalence of thyroid 
dysfunction 23 (16%). Association of autoimmnune antibodies 
and hypothyroidism was significant (p- 0.002).  
 Among the children with overt hypothyroidism 17 (73%) were 
positive for TPO antibodies, 12 (52%) were positive for TG 
antibodies and 11(47%) for both of these antibodies. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
0
5
10
15
20
25
TPO
17
6
O
v
e
rt
 H
y
p
o
th
y
ro
id
is
m
Antibody Positivity within Overt 
Hypothyroidism
30 
Fig 3: 
TG BOTH
12 11
11 12
 
31 
 
 5 (3.5%) children had lab evidence of hypothyroidism but 
negative for antibodies.  
 12 (8.4%) children were positive for antibodies but no lab 
evidence for hypothyroidism. 
  None had the clinical features of hypothyroidism. 
In these TIDM children with presence of any of these antibodies ( 
anti-TPO and anti-Tg  ) correlation was done with sex, duration of 
diabetes,  age at onset of hypothyroidism, lipid profile including 
cholesterol and triglycerides, glycemic control using HbA1C, 
presence of thyroid enlargement, presence of thyroid 
echogenecity on USG, and subclinical hypothyroidism. BMI was 
compared in these individuals with and without AIT.   
 In 2 of  these 32 children (6.2%)  were positive for AIT at the 
onset of diabetes.   
 Anti-TPO antibodies were found positive at  3.01 ± 3.5 years 
after the onset of diabetes. Anti-Tg were positive 3.5 ± 2.5 years  
after the onset of diabetes. Both anti-TPO and anti-Tg were 
found positive 3.6 ± 2.5 years after the onset of diabetes. 
  The  mean ± SD age at onset of hypothyroidism with positive 
TPO antibodies was 6.97 ± 3.53 years , with Tg antibodies it 
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was 6.64 ± 3.4 . The mean ± SD BMI of the children without 
AIT was 15.8 ± 1.5 while the mean BMI in children with AIT 
was 18.5 ± 2.6.  
 The prevalence of goiter in the study group with positive TPO 
antibodies was 16 (94%), with TG antibodies it was 13(76.5%) 
and it was 12 (70.6%) when positive for both antibodies. 
Multivariate logistic regression analysis was done to correlate age at 
onset of hypothyroidism, gender, duration of diabetes, against AIT. 
The effect of  AIT on the glycemic control, lipid abnormality, BMI 
were analysed. In children with AIT, the presence of thyroid 
enlargement and sonographic evidence of AIT were also analysed. 
(Table 1,2,3,4,5) 
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Table 1: Univariate analysis showing comparision of factors with 
TPO positivity 
      n=30     
CHARCTERISTICS N POSITIVITY % P-VALUE RESULT 
SEX           
Male 52 3 5.8     
Female 90 27 30.0 0.002 Sig 
HYPOGLYCEMIC EPISODE           
No episode 100 23 23.0     
1 or more 42 7 16.7 0.399 NS 
CHOLESTROL           
Normal 119 18 15.1     
Abnormal 23 12 52.2 0.003 Sig-f 
TRIGLYCERIDES           
Normal 120 20 16.7     
Abnormal 22 10 45.5 0.002 Sig-f 
BOTH           
34 
 
Normal 128 22 17.2     
Abnormal 14 8 57.1 0.002 Sig-f 
HbA1C           
Fair  101 17 17.0     
Poor 41 13 31.7 0.049 Sig 
GOITRE           
Present 17 16 94.1     
Absent 125 14 11.2 0.001 Sig-f 
USG-AIT           
Present 18 17 94.4     
Absent 124 13 10.5 0.001 Sig-f 
SUBCLINICAL HYPOTHYROIDISM           
Absent 133 26 19.5     
Present  9 4 44.4 0.077 NS 
 
 
 
 
 
 
 
 
     
      
35 
 
CHARCTERISTICS n POSITIVITY   P-VALUE RESULT 
    MEAN(S.D)       
BMI 30 15.7(1.5)   0.252 NS 
DURATION 30 3.01(2.48)   0.001 Sig 
BMI1 30 18.55(2.64)   0.465 NS 
 
P < 0.05, statistically significant- chi square test, f-fischer test  
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Table 2: Univariate analysis showing comparision of factors with 
TG positivity 
CHARCTERISTICS   POSITIVITY % P VALUE RESULT 
SEX           
Male 52 1 1.9 0.001 Sig 
Female 90 20 22.2     
HYPOGLYCEMIC EPISODE           
No episode 100 15 15.0     
1 or more 42 6 14.3 0.913 NS 
CHOLESTROL           
Normal 119 13 10.9 0.007 Sig-f 
Abnormal 23 8 34.8     
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TRIGLYCERIDES           
Normal 120 13 10.8 0.005 Sig-f 
Abnormal 22 8 36.4     
BOTH           
Normal 128 14 10.9 0.001 Sig-f 
Abnormal 14 7 50.0     
HbA1C           
Normal 101 12 11.9 0.126 NS 
Abnormal 41 9 22.0     
GOITRE           
Present 17 13 76.5 0.002 Sig-f 
Absent 125 8 6.4     
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USG-AIT           
Present 18 14 77.8 0.023 Sig-f 
Absent 124 7 5.6     
SUBCLINICAL HYPOTHYROIDISM           
Absent  133 19 14.3 0.622 NS 
Present  9 2 22.2     
CHARCTERISTICS n POSITIVITY   P Value RESULT 
    MEAN(S.D)       
BMI 21 15.8(1.5)   0.594 NS 
DURATION 21 3.5(2.4)   0.004 Sig 
BMI1 21 18.7(2.5)   0.304 NS 
P < 0.05, statistically significant- chi square test, f-fischer test  
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Table 3: Univariate analysis showing comparision of factors with 
Both TPO and TG positivity 
TPO and TG 
CHARCTERISTICS   POSITIVITY % P value RESULT 
SEX           
Male 52 1 1.9 0.002 Sig 
Female 90 18 20.0     
HYPOGLYCEMIC EPISODE           
No episode 100 14 15.0     
1 or more 42 5 14.3 0.913 NS 
CHOLESTEROL           
Normal 119 12 10.1 0.009 Sig-f 
Abnormal 23 7 30.4     
TRIGLY           
Normal 120 12 10.0 0.006 Sig-f 
Abnormal 22 7 31.8     
BOTH           
Normal 128 13 10.2 0.001 Sig-f 
Abnormal 14 6 42.9     
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HbA1C           
Nor 101 10 9.9   NS 
Abn 41 9 22.0 0.056   
GOITRE           
Present 17 12 70.6 0.021 Sig-f 
Absent 125 7 5.6     
USG-NECK           
Present 18 13 72.2 0.003 Sig-f 
Absent 124 6 4.8     
SUBCLINICAL HYPOTHYROIDISM           
Absent 133 18 13.5 0.836 NS 
Present  9 1 11.1     
CHARCTERISTICS N POSITIVITY   P value RESULT 
    Mean(S.D)       
BMI 19 15.8(1.5)   0.617 NS 
DURATION 19 3.6(2.5)   0.002 Sig 
BMI1 19 18.8(2.5)   0.25 NS 
P < 0.05, statistically significant- chi square test, f-fischer test  
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Logistic regression analysis to estimate the risk factors associated 
with autoantibody positivity in T1DM children 
Table 4: TPO positivity 
  P value OR 95% C. I 
1. Sex  0.299 0.104 0.029 – 0.376 
2. Cholesterol  0.057 7.827 0.940 – 65.197 
3. Triglycerides 0.553 0.361 0.012 – 10.488 
4. Both  0.023 6.003 3.454  – 8.491 
5. HbA1C 0.482 2.225 0.239 – 20.670 
6. Goitre 0.003 4.044  2.001-5.992 
7. USG 0.003 5.84 4.802 – 5.920 
 
P < 0.05, statistically significant- chi square test, 
OR- odds ratio, CI- confidence interval  
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Table 5: Tg positivity 
  P value OR 95% C. I 
1. Sex  0.154 8.432 0.449 – 158.38 
2. Cholesterol  0.499 2.356 0.197 – 28.259 
3. Triglycerides 0.520 0.244 0.003-17.941 
4. Both  0.884 0.682 0.002 – 1.043 
5. HbA1C 0.354 1.234 0.008 – 1.432 
6. Goitre 0.002 4.470 3.04- 6.558 
7. USG 0.002 5.168 4.056 – 6.091 
 
P < 0.05, statistically significant- chi square test, 
OR- odds ratio, CI- confidence interval  
 
 
 
 
 
 
  In children with TPO positivity n
and 3(10%) were males.
20(95%) were females and 1(5%) were males. When both 
antibodies are positive 18( 94.7%) were seen in females and 
1(5.3) were seen
preponderance among antibody positive T1DM children. Both 
univariate and multivariate analysis showed
significance between thyroid antibody positivity and 
gender. (Table 1,2,3,4,5).
0
5
10
15
20
25
30
TPO
3
27
Sex Predilection in Antibody Positivity 
43 
early 27(90%) were females 
 Among the Tg positive children 
 in males. Thus overall there was
  
  
Fig 4: 
TG BOTH
1 1
20 18
Male Female
 a female 
statistical 
female 
 
  In children with positive TPO antibodies,
thyroid enlargement (goitre) 
0.001 – 1.992 
hypoechogeni
CI 2.01-3.774 
(53.3%) showed
1.004 , 95% CI 
sonographic evidence of AIT.
3.24-5.78 ). In 
seen in 12(63.2%
of AIT was seen in 13 children(68.4%)
0
TPO
TTG
BOTH
Goitre and Hypoecho genecity with 
44 
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(P= 0.001, OR 1.004 , 95% CI 
) and 17 (56.7%)  children showed
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  In patients with positive TPO antibodies  only 4 (13.3%) had 
subclinical hypothyroidism. (p= 0.0
positive Tg
hypothyroidism. (p=0.622). In children with both antibodies 
positive only 1(5.3%) had subclinical hypothyroidism. 
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 Hypercholesterolemia was seen in 12(40%) children with 
positive TPO antibodies(p=0.002) while it was 8(38.1%) with 
positive Tg antibodies(p=0.007) and 7 (30.4%)  in children with 
both antibodies positive(p=0.009). Hypertriglyceridemia was 
seen in 10(33.3%) children with positive TPO 
antibodies(p=0.001) while it was 8(36.4%) with positive Tg 
antibodies(p=0.005) and 7 (36.8%)  in children with both 
antibodies positive(p=0.001). Both hypercholesterolemia and 
hypertriglyceridemia was seen in 8(26.7%) children with 
positive TPO antibodies (p=0.002) while it is 7(33.3%) with 
positive Tg antibodies (p=0.001) and 6 (31.6%)in children with 
both antibodies positive(p=0.001).  
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  In children with positive TPO antibodies, 7(26.3%) had 
hypoglycemic episodes (p=0.399) while with positive TTG 
antibodies 6(28.6%) had hypoglycemic episodes
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DISCUSSION 
  The present study  showed that children with T1DM had high 
levels of both anti-TPO and anti-Tg antibodies. AIT is the most 
prevalent autoimmune disorders associated with T1DM(20,35). The 
reason for the high prevalence of some autoimmune disorders in these 
patients still remains undetermined. It may be due to a increased 
tendency to act against specific antigens, or loss of self recognition 
particularly when there is genetic or environmental trigger.(36). 
 
According to some studies, HLA(30,31) or some genetic 
component outside the HLA  (i.e., CTLA4  and PTPN22 ) might be a 
reason (37,38) in the occurrence of AIT in T1DM patients. Moreover, 
environmental triggers such as  any stressful event, infection, trauma 
may also play a role. Both T1DM and AIT are diseases which occurs 
as a result of autoimmunity mediated through T-cell pathway. (39). 
 
In the present study, the prevalence of positivity for anti-TPO 
Antibody, anti-Tg antibody, and the prevalence of positivity for both 
antibodies and AIT (at least one positive antibody) in children with 
T1DM were 21%, 14%,13% and 22.5% respectively (Fig 2). In other 
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studies, the prevalence of positive anti-TPO antibody in T1DM 
patients was reported to be 5.5-46.2% and that of anti-Tg antibody 
ranged from 2.1 to 40%. Thus like in previous studies TPO antibody 
has higher positivity.The wide range of these data can be explained by 
the difference in genetic factors, age, and sex of the studied 
population,(40) as well as the different methods of measurement of 
antibodies.(8)  
 
Most studies that have reported low prevalence of AIT were 
conducted 10-20 years ago,which shows the low sensitivity of the lab 
tests. Meanwhile, this finding might also be a result of increase in the 
prevalence of AIT during the recent decades(8) along with increasing 
TIDM cases. Epidemiologic studies have shown higher incidence of 
AIT after elimination of iodine deficiency in endemic areas.(39) The 
lower prevalence of AIT in our study could be explained by the 
different age group of studied individuals in our study. However, the 
present study was conducted on children and showed comparable 
results with other studies performed in similar age group. Age 
dependent increase of AIT incidence has  been described 
previously.(42) 
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 From previous studies the prevalence of clinical and subclinical 
thyroid dysfunction in T1DM patients is suggested to be 13.4-20% (40) 
whilst the prevalence of hypothyroidism and hyper-thyroidism in the 
normal population is 5-10% and 1%,respectively.(7) 
 
A significant percentage of them were found to have AIT  very 
early after the onset of diabetes. In the present study, there was no 
case of clinical thyroid dysfunction. However, there was lab evidence 
of hypothyroidism and also thyroid enlargement were seen in those 
cases which has overt or antibody positive hypothyroidism (Fig 3,5 ). 
Subclinical hypothyroidism was present in 8% (Fig 1).  In our study, 
the prevalence of subclinical hyperthyroidism in T1DM patients was 
0%, which is consistent with the findings of previous studies.(3)  
We found that diabetic patients with AIT had higher prevalence 
of  thyroid hormones, which was statistically significant.(Fig 3). 
Therefore, the higher prevalence of subclinical hypothyroidism in 
T1DM patients could be explained by the high prevalence of AIT 
(22.5%) in these patients. 
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                 Unfortunately,  iodine status of the studied population was 
not evaluated and as a result, we could not investigate the role of 
iodine deficiency in the high prevalence of subclinical 
hypothyroidism. In the present study, the prevalence of goiter in 
T1DM was 11.2 % . The lower prevalence of goiter in T1DM patients 
is in contrast with previous studies,which showed increase in goiter 
prevalence in T1DM patients.(43-45). However in our study there is 
higher prevalence of goiter in T1DM patients with AIT(94%) (Fig 5) 
which is statistically significant. Urine iodine concentration in T1DM 
patients was previously reported to be high (46). Goiter was made by 
inspection and palpation. All the cases clinically suspected to have 
goiter were confirmed by thyroid ultrasonography.  
                   In our study, the prevalence of AIT in female patients with 
T1DM was higher than that in male T1DM patients which is 
consistent with many studies with higher prevalence of positive 
thyroid autoantibodies in females(47) though some studies reported 
similar prevalence in both genders. (48,49) In T1DM children with AIT, 
oestrogen were found to increase the risk of autoimmunity by acting 
through the T cell pathway, while androgens usually protects against 
this.(56) 
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In our study, the prevalence of AIT is increased with  age and duration 
of diabetes. These observations in our study are similar to previous 
studies(11,54). This has lead to the suggestion  that autoimmunity is the 
end result which started with self recognition, then passes through 
immunity followed by  appearance of antibodies finally leading to 
autoimmune disease.(56) In our study,  in children with AIT, duration 
of diabetes was found to have statistical significance in the univariate 
analysis. As the duration increases the prevalence of AIT  increases. 
Thus strongly reinforces that along with initial screening, these 
children with AIT should have a long term follow up. 
In contrast to previous studies(5), in the current study, we found a 
relationship between HbA1c, a measure of metabolic control in 
diabetic patients, and AIT or thyroid dysfunction. In TPO positive 
children there was a statistical significance, while in Tg and both 
antibody positivity there was no statistical significance. (Tab 1,2,3; 
Fig 8). This clearly points out that  children with AIT might have 
fluctuating glycemic control and diabetic management can be made 
difficult.  Another explanation that can be given for no statistical 
significance is that cut off of 10 was taken as to be having poor 
control. But ideally < 6 is normal and for good control it should be 
56 
 
atleast 6-8. It is well known fact that  T1DM children with AIT are 
prone to have poor glycemic control. 
 
In TIDM children with AIT, there is significant elevation in lipid 
parameters including both cholesterol and triglycerides.(Fig 7; Tab 1-
5) which is in consistent with previous studies. Here there is a  
statistical significance for both cholesterol and triglycerides when 
compared for both the antibodies which is an extremely important 
finding. As such the long term morbidity is increased, hence these 
should be looked into while managing these children. Also we have 
found a significant elevation in a very early age. Hence they should be 
regularly followed up to avoid other cardiovascular complications. 
 
Though the hypoglycemic episodes did not have statistical 
significance in our study (Tab 1-5, Fig 9) it is an important 
complication known to occur in diabetic children with 
hypothyroidism. Again here hypoglycemic episodes were taken as 
significant when there is documented low sugar along with other 
manifestations like palpitations, sweating or seizures. It is a known 
fact these children are more prone for hypoglycemia. Hence proper 
counseling need to be given regarding recognition of symptoms. 
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Another important observation of our study was that the 
influence of AIT on  BMI, showed no statistical significance like in 
other studies.(11,29). But, Chase et al (28)  has observed decreased growth  
in T1DM children with AIT. But difference was noted in children with 
and without AIT. (Fig 10) Thyroxine if  given early leads to improved 
growth in these children. This observation has highlighted the 
significance of the early identification and treatment of AIT in these 
individuals. Though BMI didn’t had statistical significance these 
children should be followed in long term basis to exactly arrive at a 
conclusion.  
It was also observed that in the presence of both thyroid antibodies, 
the autoimmune process is more vigorous, causing AIT.  Among both 
the antibodies, TPO were found to be more specific to detect AIT..(11) 
 
 
 
 
 
58 
 
 
COMPARISION OF AIT IN VARIOUS STUDIES: 
 
Ardestani et al 22% 
Kostas kokleas et al  Tpo-17.3%, Ttg-11.3%, both 
10.4% 
Ismael et al  15% 
Kordonouri et al  Tpo 15.4%, Ttg 14.4% 
Guillermo et al 17.91% 
This study Tpo-21%, Tg-14%, both- 13% 
0verall-22.5% 
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Fig : 11 
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Parameters  This study Previous studies 
AIT at the diagnosis of 
diabetes 
6.2% 16.7 (Guillermo et al) 
Hyperthyroidism  0% 1-2%  (Ardestani et 
al) 
Mean age at onset of 
AIT 
6 years 15 years (Pranzy et 
al) 
 
Mean duration of 
diabetes 
3.5 years 4.6 years (Kostas et 
al) 
Prevalence of goiter 11.2% 21% (Ardestani et al) 
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CONCLUSION 
Hypothyroidism is predominantly autoimmune in T1DM 
children. Mostly it is asymptomatic. This emphasizes the need for 
regular thyroid screening in diabetic children. Children with T1DM 
had higher prevalence of AIT. To conclude, the presence of thyroid 
antibody positivity was common among our T1DM children.   
Important among the risk factors for AIT to develop in these children 
include increasing age , female sex, longer duration of diabetes.  
 
Importantly AIT significantly affects lipid status of the body 
which increases the long term morbidity in these children. Presence of 
AIT makes the glycemic control difficult, predisposing these 
individuals to hypoglycemia. Though  AIT has not been found to 
affect the growth of T1DM children it is extremely important in long 
term to monitor BMI . 
Hence it is recommended that all patients with T1DM should 
undergo screening for AIT at the time of diagnosis of diabetes and 
then yearly or atleast 2-3 yearly. If  thyroid antibody is positive they 
should be followed up regularly. Presence of thyroid antibody is not 
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an indicator to start treatment. Current recommendation is that 
treatment is decided based on the level of TSH. 
Importance of diagnosing AIT lies in the fact that these 
individuals are more prone to develop thyroid dysfunction and that 
early diagnosis aids to initiate treatment early. To  summarize, the 
antibodies should be screened in T1DM children to find AIT, but its 
value  to predict the progression of the clinical manifestation is 
limited. These patients with positive antibodies should be followed up 
because further deterioration of the thyroid gland may occur. 
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RECOMMENDATION: 
 Screening for thyroid disease in type 1 diabetic children should 
be initiated at diagnosis. 
 Preferably it should be checked annually, or at least every 2-3 
years. 
 The preferred method of screening is using TSH.  
 Other method of screening includes thyroid peroxidase 
antibody. 
 Thyroid antibody positivity alone is not an indication for 
treatment in these children, but they have a increased risk to 
develop thyroid dysfunction. 
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LIMITATIONS OF THE STUDY: 
 Iodine status of our diabetic children was not estimated 
 Prevalence of AIT in normal children was not assessed and 
hence could not be compared with our T1DM children. 
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TIME SCHEDULE 
Protocol finalization – July 2011 
 Study period – August  2011-  Oct 2012 
 Manuscript preparation – November 2012 
 Manuscript Submission – December 2012 
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ABBREVIATIONS 
TIDM – Type 1 diabetes mellitus 
TPO – Thyroid peroxidase 
TG  - Thyroglobulin 
AIT - Autoimmune thyroiditis 
 USG - Ultrasonography 
BMI - Body Mass Index 
  
  
INFORMATION SHEET 
 
Place of study: INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN, 
Diabetic OPD 
Name of Investigator :   
Name of Participant    age:   sex:  
Hospital No:       Diabetic  No: 
Study title : Study on  prevalence of thyroid dysfunction in type 1 diabetic children 
• We are conducting a study on  prevalence of thyroid dysfunction in type 1 diabetic 
children. 
We request you to participate in the study 
• The purpose of this study is to study the prevalence of thyroid dysfunction in type 1 
diabetic children. 
 • The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
• Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of benefits 
to which you are otherwise entitled. 
• The results of the special study may be intimated to you at the end of the study period or 
during the study if anything is found abnormal which may aid in the management or 
treatment. 
 
 
 
 
 
  
INFORMED CONSENT FORM 
Study place: INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN, Diabetic OPD 
Title of the study:  study on the prevalence of thyroid dysfunction in type 1 diabetic children. 
 
Name of the investigator        
Name of the Participant:  Age:   Sex: 
Hospital number:   Diabetic no: 
    
1. I have read and understood this consent form and the information provided to me 
regarding the participation in the study.  
2. I have had the consent document explained to me.  
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the investigator.  
5. I have informed the investigator of all the treatments I am taking or have taken in the 
past  
including any native (alternative) treatment.  
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer  
unusual symptoms. * 
8. I have not participated in any research study in the past. 
10. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason  
and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the study at 
any time, for  
any reason, without my consent. * 
  
12. I hereby give permission to the investigators to release the information obtained 
from me as result  
of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and 
IEC. I  
understand that they are publicly presented.  
13. I have understand that  my  identity will be kept confidential if my data are publicly 
presented  
14. I have had my questions answered to my satisfaction.  
15. I have decided to be in the research study.  
I am aware that if I have any question during this study, I should contact the 
investigator. By signing  
this consent form I attest that the information given in this document has been clearly 
explained to me  
and understood by me, I will be given a copy of this consent document. For adult 
participants:  
Name and signature / thumb impression of the participant /parents/guardian  
Name _________________________ Signature_________________ 
Date________________  
Name and Signature of impartial witness:  
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of the investigator or his representative obtaining consent:  
Name _________________________ Signature_________________ 
Date________________  
 
 
 
  
  
  
Annexure : Patient data entry form 
 Name of the patient: 
 Present age: 
 Age at onset of diabetes: 
 Gender:  
 Duration of diabetes: 
 Palpation of thyroid gland  
 Body mass index 
 Biochemical parameters: 
         Thyroid profile: T3,T4,TSH 
         Thyroid peroxidase antibodies, Thyroglobulin antibodies  
   Lipid profile 
 No. of hypoglycemic episodes 
    HbA1C  
 USG neck 
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